, a respected provider of sports medication product advancement and educational solutions for orthopedic surgeons based in Naples, Florida, announced today that they signed a secured asset purchase contract dated as of January 24, 2011 to market most of Cardo’s joint arthroplasty division, which comprise all of its knee and hip resources, to Arthrex. Cardo will document a Current Report on Type 8-K with the Securities and Exchange Commission within the next four business times. Cardo is continuing to explore various other strategic options for its Backbone division. Cardo’s and Arthrex’s Board of Directors have accepted and followed the Asset Purchase Agreement and the deal contemplated thereby.This extensive research was funded by the Johns Hopkins Center for Complementary and Alternative Medicine. Participants in this study are Jason L. Parker, Sabra L. Klein, Warwick L. Morison, and Xaobu Ye from the Johns Hopkins; Martha McClintock from the University of Chicago; Claudio J. Conti from the M.D. Anderson Cancer Center; and Carlos Nousari from the University of Miami.
Chronic disease as great a threat as terrorists According to international professionals the global threat from chronic disease is as great as the threat of terrorism and inadequate is being done to fight it.